4D Molecular Therapeutics (FDMT) closed at $10.23 on November 20, 2026, down 4.6% from the previous close, on volume of 648,195 shares (30-day average 905,208).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 13, 2026 | Put with Delta Hedge | 15-Jan-27 12 P +40,000 Stock | 1,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 20, 2026. See the largest for 5, 30, 60 and 90 days
TipRanks (Mon, 16-Nov 7:40 AM ET)
4D Molecular Therapeutics: Buy Rating Reiterated on 4D-150 Progress; $36 Price Target Maintained
TipRanks (Mon, 16-Nov 6:36 AM ET)
4DMT Announces New Employment Inducement Grants
Globe Newswire (Fri, 13-Nov 4:05 PM ET)
Globe Newswire (Thu, 12-Nov 4:05 PM ET)
4DMT to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 8:00 AM ET)
FDMT Sets October 21, 2026 Investor Day Spotlighting Phase 3 Retina Program 4D-150
Market Chameleon (Mon, 5-Oct 7:53 AM ET)
4DMT to Host Investor Day on October 21, 2026
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
Globe Newswire (Mon, 28-Sep 8:00 AM ET)
FDMT Secures $100 Million in Fresh Funding: New Offering Expands Clinical Ambitions
Market Chameleon (Thu, 6-Nov 3:05 AM ET)
Market Chameleon (Fri, 31-Oct 3:07 AM ET)
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
4D Molecular Therapeutics trades on the NASDAQ stock market under the symbol FDMT.
As of November 20, 2026, FDMT stock price declined to $10.23 with 648,195 million shares trading.
FDMT has a beta of 1.21, meaning it tends to be more sensitive to market movements. FDMT has a correlation of 0.07 to the broad based SPY ETF.
FDMT has a market cap of $576.76 million. This is considered a Small Cap stock.
Last quarter 4D Molecular Therapeutics reported $4 million in Revenue and -$1.08 earnings per share. This beat revenue expectation by $923,904 and missed earnings estimates by -$.03.
In the last 3 years, FDMT traded as high as $36.25 and as low as $2.24.
The top ETF exchange traded funds that FDMT belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
FDMT has underperformed the market in the last year with a price return of -1.1% while the SPY ETF gained +6.9%. FDMT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.5% and -16.5%, respectively, while the SPY returned -9.3% and -6.2%, respectively.
FDMT support price is $10.08 and resistance is $11.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FDMT shares will trade within this expected range on the day.